Genscript Biotech, though in debt, retains substantial net c...

Genscript Biotech, though in debt, retains substantial net cash, suggesting manageable debt. Its remarkable revenue surge last year could point to future profitability, but its presently unprofitability at the EBIT level and recent negative cash outflows suggest more capital might be needed. The overall risk for Genscript Biotech is notable at this point.